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Background: Morus alba, a medicinal plant in Asia, has been used traditionally to treat diabetes mellitus and
hypoglycemia. However, the effects of M. alba extract (MAE) on atopic dermatitis have not been verified
scientifically. We investigated the effects of MAE on atopic dermatitis through in vitro and in vivo experiments.
Methods: We evaluated the effects of MAE on the production of nitric oxide (NO) and prostaglandin E2 (PGE2) in
RAW 264.7, as well as thymus and activation-regulated chemokine (TARC/CCL17) in HaCaT cells. In an in vivo
experiment, atopic dermatitis was induced by topical application of house dust mites for four weeks, and the
protective effects of MAE were investigated by measuring the severity of the skin reaction on the back and ears,
the plasma levels of immunoglobulin E (IgE) and histamine, and histopathological changes in the skin on the
back and ears.
Results: MAE suppressed the production of NO and PGE2 in RAW 264.7 cells, as well as TARC in HaCaT cells, in a
dose-dependent manner. MAE treatment of NC/Nga mice reduced the severity of dermatitis and the plasma
levels of IgE and histamine. MAE also reduced the histological manifestations of atopic dermatitis-like skin
lesions such as erosion, hyperplasia of the epidermis and dermis, and inflammatory cell infiltration in the skin on
the back and ears.
Conclusion: Our results suggest that MAE has potent inhibitory effects on atopic dermatitis-like lesion and may
be a beneficial natural resource for the treatment of atopic dermatitis.
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Atopic dermatitis is a multifactorial disease that depends
on a genetic predisposition to allergy, which is character-
ized by complex immune mechanisms in the development
of allergic skin inflammation [1]. Complex interrela-
tionships between genetic, environmental, skin barrier,
pharmacological, psychological and immunological factors
contribute to the pathogenesis of atopic dermatitis, but its
immunological basis is of considerable importance, and it
has been studied extensively [2]. Immunological analyses
of atopic dermatitis have shown that the activation of mast
cells and differentiated T-helper 2 (Th2) cells by various* Correspondence: hkshin@kiom.re.kr
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reproduction in any medium, provided the ormediators have major roles in the development of derma-
titis [3,4]. Previous studies have shown that atopic derma-
titis is associated with increased serum immunoglobulin
(Ig) E levels, the Th2 chemokine level in the lesional skin,
the serum eosinophil count, and the expression of proin-
flammatory enzymes such as nitric oxide (NO) and pros-
taglandin E2 (PGE2) [5,6].
Morus alba L. (Moraceae) is a traditional medicinal
herb used for the prevention and treatment of several
diseases, such as jaundice, hematemesis, and pollakisuria
[7,8]. Phytochemical studies of M. alba have identified
alkaloids, flavonoids, glycosides, terpenoids, steroids,
volatile oils and tannins [9-11]. The biological activities
of M. alba include antidiabetic, hypolipidemic, antihyper-
tensive, antimicrobial, antioxidant, antiatherosclerotic,
anticancer, neuroprotective, and antiulcer effects [12-16].. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly credited.
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atopic dermatitis. Therefore, we investigated the effect of
M. alba extract (MAE) on NO and PGE2 production in
RAW 264.7 macrophages, and thymus and activation-
regulated chemokine (TARC) production in HaCaT kera-
tinocytes. We examined the effects of MAE on NC/Nga
mice as a model of house dust mite-induced atopic derma-
titis. We measured the skin severity score, histological
changes in the skin, including mast cell infiltration, and the
plasma IgE and histamine levels. The effect of MAE might
be associated with the suppression of the inflammatory
response in atopic dermatitis.
Methods
Reagents and materials
Dried M. alba (200 g) was extracted three times with
70% ethanol (2 L) by sonication for 60 min. The extract
was filtered, evaporated to dryness, and freeze-dried
(11.35 g). The yield was 5.68%. The M. alba used in this
experiment was purchased from HMAX (Jecheon, Korea)
in October 2008. The origin of the sample was confirmed
taxonomically by Professor Je-Hyun Lee, Dongguk
University, Gyeongju, Republic of Korea. A specimen
(2008-ST12) has been deposited in the Basic Herbal
Medicine Research Group, Korea Institute of Oriental
Medicine.
Biostir-AD®, an ointment that contains house dust
mite (Dermatophagoides farina) extract, was purchased
from Biostir Inc. (Kobe, Japan), while 0.1% Tacrolimus
(Protopic®; Astellas, Grand Island, NY, USA) was used as
a the positive control.
Cell culture
The murine macrophage RAW 264.7 cells and human
keratinocyte HaCaT cells were obtained from the American
Type Culture Collection (Rockville, MD, USA). They
were cultured in Dulbecco’s modified Eagle’s medium
(Gibco Inc., Grand Island, NY, USA) supplemented
with 5.5% (for Raw 264.7) or 10% (for HaCaT) heat-
inactivated fetal bovine serum (Gibco Inc.), penicillin
(100 U/mL), and streptomycin (100 μg/mL) in a 5% CO2
incubator at 37°C.
Cell viability
Cell viability was assessed with the CCK-8 assay (Cell
Counting Kit-8, Dojindo Laboratories, Kumamoto, Japan)
according to the manufacturer’s instructions. RAW 264.7
cells (3 × 103 cells/well) and HaCaT cells (1 × 103 cells/well)
were incubated in 96-well plates with various concentra-
tions of the MAE for 24 h. CCK-8 reagent was added to
each well and incubated for 4 h. The absorbance was mea-
sured at 450 nm with a Benchmark plus microplate reader
(Bio-Rad Laboratories, Hercules, CA, USA). The per-
centage of cell viability was calculated with the followingformula: cell viability (%) = (mean absorbance in test wells/
mean absorbance in control wells) × 100.
Measurement of nitrite and PGE2 production
RAW 264.7 cells were plated at a density of 2.5 × 105
cells/well on 48-well plates and incubated overnight. The
cells were treated with lipopolysaccharide (LPS, 1 μg/mL)
in the absence or presence of various concentrations of
MAE. After incubation for 24 h, the supernatants were
used to determine the levels of nitrite (Griess Reagent
System, Promega Co., Madison, WI, USA) and PGE2
(PGE2 enzyme linked immunosorbent assay (ELISA) kit,
Cayman Chemical Co., Ann Arbor, MI, USA).
Measurement of TARC production
HaCaT cells (1 × 106 cell/well) were cultured on six-well
plates. After reaching a confluent state, the cells were
washed and treated with MAE in 1 mL of serum-free
medium containing tumor necrosis factor (TNF)-α and
interferon (IFN)-γ (each 10 ng/mL; R&D Systems Inc.,
Minneapolis, MN, USA) for 24 h. The supernatants were
harvested, and TARC production was quantified using an
ELISA kit (R&D Systems Inc., Minneapolis, MN, USA).
Experimental animals
Male NC/Nga mice (eight weeks old) were purchased
from Central Laboratory Animal Inc. (Seoul, Korea). The
animals were housed in an air-conditioned room and main-
tained at 24 ± 2°C and 55 ± 15% humidity. All experimental
procedures were carried out in accordance with the NIH
Guidelines for the Care and Use of Laboratory Animals
and were approved by Korea Institute of Oriental Medicine
Institutional Animal Care and Use Committee (Approval
number: #10-052).
Induction of atopic dermatitis in NC/Nga mice
Atopic dermatitis-like skin lesions were induced in
10-week-old male NC/Nga mice using Biostir-AD, as
described by the manufacturer with some modifications
[17]. Briefly, the upper back was shaved, and 200 μL of 4%
(w/v) sodium dodecyl sulfate (SDS) was applied to the
shaved dorsal skin and both surfaces of each ear for bar-
rier disruption. After 2 h, 50 mg of Biostir-AD was applied
topically and twice per week for four weeks. The mice
were allocated to four random groups (n = 7/group): nor-
mal control group (vehicle-treated mice; 70% ethanol/PBS
(ratio 1:9), 200 μL/mouse), Biostir group (Biostir-AD plus
vehicle-treated mice), Tacrolimus group (Biostir-AD plus
Tacrolimus ointment-treated mice; 50 μg/mouse), and MAE
group (Biostir-AD plus MAE-treated mice; 10 mg/mouse).
The effective dose of MAE was determined according to
preliminary study. We have used 10 mg/kg and 20 mg/kg
of MAE as experimental doses in preliminary study. The
procedure of preliminary study was same to present study.
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20 mg/kg of MAE compared with the animal with atopic
dermatitis. However, the skin severity of 10 mg/kg more
decreased than that of 20 mg/kg. MAE was dissolved 70%
ethanol/PBS (ratio = 1:9) and applied every day for four
weeks. The mice were sacrificed under anesthesia with
pentobarbital (200 μg/mouse, i.p.) on the day of the ex-
periment. During the autopsy, blood was collected from
the posterior vena cava, and the back skin and each ear
were excised for the histopathological analyses.
Evaluation of skin severity
The relative severity of dermatitis was assessed macro-
scopically according to the Eczema Area and Severity
Index (EASI) scoring system: 0, no symptoms; 1, mild
symptoms; 2, moderate symptoms; and 3, severe symptoms.
The dermatitis score was defined as the sum of the scores
for erythema/hemorrhage, edema, excoriation/erosion,
and scaling/dryness [18]. The range of dermatitis score
is 0 to 12. The mice were also photographed once each
week. The dermatitis scoring is conducted throughout
blind test. Two veterinarian and three animal study experts
participated in blind test.
Histopathology
After sacrifice, the back skin and one ear of each mouse
were fixed in 10% (v/v) neutral buffered formalin for
24 h at 4°C. Tissue samples were embedded in paraffin and
thin-sectioned (4 μm thickness). The sections were stained
with hematoxylin and eosin (H&E) solution (Sigma-Aldrich,
St. Louis, MO, USA) and mounted under cover slips using
Dako-mounting medium (Dako Cytomation, Glostrup,
Denmark). The stained sections were photographed using
a photometric Quantix digital camera, and montages were
assembled using Adobe Photoshop. To measure the degree
of mast cell infiltration, the skin sections were stained with
toluidine blue, and the numbers of mast cells were counted
in four sites. The histological alternation of tissue was exam-
ined by two histopathologists.
Measurement of plasma IgE and histamine levels
Blood samples were drawn from the mice, separated by
centrifugation at 10000 × g for 10 min at 4°C, and stored
at −80°C. The levels of histamine (Oxford Biomedical
Research, Oxford, MI, USA) and IgE (Bethyl Laboratories
Inc., Montgomery, TX, USA) were measured in the
plasma using ELISA kits, according to the manufac-
turer’s instructions.
Statistical analyses
All of in vitro experiments were performed at least
three times. The dermatitis score was analyzed using
Mann-Whitney’s U test. The concentration of IgE, hista-
mine, PGE2, nitrite and TARC were analyzed by one-wayanalysis of variance (ANOVA) followed by Dunnett’s test.
The difference was considered significant at P < 0.05.
Results
MAE inhibits nitrite and PGE2 production in LPS-stimulated
RAW264.7 cells
The cytotoxicity of MAE was determined in RAW 264.7
and HaCaT, subsequent experiments were performed in
cells at non-toxic concentrations (Figure 1). To determine
the effects of MAE on nitrite and PGE2 production,
RAW264.7 cells were treated with various concentrations
of MAE (1, 10, or 100 μg/mL) followed by stimulation
with LPS (1 μg/mL) for 24 h. LPS strongly stimulated
nitrite production (51.01 ± 2.178 nM) in RAW 264.7 cells.
By contrast, MAE significantly reduced nitrite production
(24.20 ± 1.818 nM, P < 0.01) at a dose of 100 μg/mL com-
pared with that in the LPS-stimulated RAW 264.7 cells
(Figure 2A). LPS-stimulated RAW 264.7 cells had higher
PGE2 production (9.90 ± 0.957 ng/mL, P < 0.05) compared
with the untreated control (5.43 ± 0.502 ng/mL), whereas
MAE reduced the PGE2 level significantly (6.28 ± 0.102 nM,
P < 0.05) at 100 μg/mL compared with LPS stimulation
(Figure 2B).
MAE inhibits TARC production in TNF-α and IFN-γ
stimulated HaCaT cells
We tested the effects of MAE on TARC production in
TNF-α and IFN-γ (TI)-stimulated HaCaT cells. The cells
were treated with various concentrations of MAE extract
(20, 50, or 100 μg/mL) followed by stimulation with TI
(10 ng/mL) for 24 h. MAE suppressed TI-stimulated TARC
production in a dose-dependent manner (Figure 3). The
TI-treated cells exhibited a significant increase in TARC
production (24.43 ± 0.879 pg/mL, P < 0.01) compared
with the untreated control cells (2.44 ± 0.437 pg/mL).
The increased of TARC production was reduced to
12.79 ± 1.955 pg/mL, 3.69 ± 0.835 pg/mL, and 1.83 ±
0.895 pg/mL by MAE treatment (P < 0.01) at 20, 50, or
100 μg/mL, respectively.
MAE suppresses the severity of dermatitis and skin lesions
in Biostir-AD-induced atopic dermatitis using NC/Nga mice
The severity of dermatitis was evaluated once each week.
The major clinical signs and symptoms developed shortly
after the mite antigen was applied to the backs of the
mice. The atopic dermatitis‐like skin lesions worsened
progressively for four weeks after the initial treatment.
Repeated application of Biostir-AD ointment induced
skin dryness, followed by mild erythema, hemorrhage,
and edema (Figure 4A). Finally, the skin became thick, with
severe erythema, hemorrhage, edema, scarring, erosion and
excoriation. However, the application of MAE suppressed
these skin symptoms. The dermatitis score of each group
was determined by summing the eczema area severity
Figure 1 Cytotoxicity of MAE in RAW 264.7 (A) and HaCaT cells (B). Cells were seeded into 96-well plates and treated with MAE
(10, 20, or 100 μg/mL) for 24 h. Cell viability was assessed using a CCK-8 assay.
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Tacrolimus group, the symptoms increased for three
weeks but declined thereafter. In the MAE group, the
dermatitis score was lower at three weeks compared
with the Biostir group. These results indicate that
MAE suppressed the spontaneously induced dermatitis
in NC/Nga mice.
MAE attenuates the atopic dermatitis-like lesions induced
by Biostir-AD
The histopathological features were assessed using spec-
imens from the back skin and ears of NC/Nga mice. As
shown in Figure 5, epidermal hyperplasia, parakeratosis,
hyperkeratosis, dermal edema, and a large numbers or
infiltrated of inflammatory cells were observed in the
control group. However, sections of the skin from the backFigure 2 Effects of MAE on LPS-stimulated nitrite and PGE2 productio
measured using the culture supernatant from cells co-treated with MAE (1, 10,
indomethacin (0.2 and 2 ng/mL) were used as positive control drugs. The bar g
vs. vehicle control group; *, ** P< 0.05 and P < 0.01 vs LPS-treated cells, respectiand ears of the MAE-treated group exhibited remarkable
reductions in epidermal hyperplasia and cellular infiltration
into the dermis. These results suggest that MAE suppressed
the Biostir-AD-induced inflammation. The normal group
showed no signs of inflammation.
MAE inhibits the IgE and histamine levels in
Biostir-AD-induced atopic dermatitis in NC/Nga mice
The plasma levels of total IgE and histamine were de-
termined in the NC/Nga mouse model. We found that
Biostir-AD (266.53 ± 14.92 ng/mL, P < 0.01) increased
the level of IgE compared with the control group
(56.67 ± 14.91 ng/mL), whereas the IgE levels in mice
administered with MAE (186.01 ± 8.07 ng/mL, P < 0.05)
were lower than those in the Biostir group (Figure 6A).
The MAE-treated group (932.47 ± 84.89 nM) had lowern in RAW 264.7 cells. The productions of nitrite (A) and PGE2 (B) was
or 100 μg/mL) and LPS (1 μg/mL) for 24 h. L-NMMA (10 and 100 μM) and
roups represent means from three independent experiments. ## P< 0.01
vely.
Figure 3 Effects of MAE on TNF-α- and IFN-γ-stimulated TARC production in HaCaT cells. The production of TARC was measured using the
culture supernatant from the cells co-treated with MAE (20, 50, or 100 μg/mL), and TNF-α and IFN-γ (each 10 ng/mL, TI) for 24 h. Silymarin
(20 or 50 μg/mL) was used as a positive control drug. The bar groups represent the means from three independent experiments. ## P < 0.01 vs
vehicle control group; ** P < 0.01 vs. TI-treated cells.
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(1266.69 ± 147.25 nM) (Figure 6B), although the dif-
ference was not significant. These results demonstrate
that MAE prevented the development of atopic dermatitis
in NC/Nga mice.Figure 4 Effects of MAE on the development of atopic dermatitis, wh
The house dust mite extract was administered to NC/Nga mice to establish
groups: normal control group (vehicle-treated mice; 70% ethanol, 200 μL/m
group (Biostir-AD plus Tacrolimus ointment-treated mice; 50 mg/mouse), a
clinical features (A) and dermatitis scores (B) were assessed using the crite
monitored once each week for four weeks. The values are expressed as theDiscussion
Atopic dermatitis is a chronic inflammatory skin disease,
which is characterized by pruritic and eczematous skin
lesions. Recently, atopic dermatitis has been increasing in
industrialized countries, and it is a multifactorial diseaseich was induced using a house dust mite extract in NC/Nga mice.
an atopic dermatitis animal model. The mice were divided into four
ouse), Biostir group (Biostir-AD plus vehicle-treated mice), Tacrolimus
nd MAE group (Biostir-AD plus MAE-treated mice; 10 mg/mouse). The
ria described in the Materials and Methods. The features were
mean ± SEM (n = 5). * P < 0.05 vs. Biostir-AD-treated mice.
Figure 5 Effects of MAE on the histological features of house dust mite-induced atopic dermatitis in NC/Nga mice. The skin and ear
tissues were excised from normal control group (vehicle-treated mice; 70% ethanol, 200 μL/mouse), Biostir group (Biostir-AD plus vehicle-treated mice),
Tacrolimus group (Biostir-AD plus Tacrolimus ointment-treated mice; 50 mg/mouse), and MAE group (Biostir-AD plus MAE-treated mice; 10 mg/mouse),
fixed with 10% formaldehyde, embedded in paraffin, and cut into thin sections. The histological features of the skin and ear lesions were determined after
staining with hematoxylin and eosin.
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infectious agents, food allergens, and aeroallergens.
These environmental components elevate the serum
IgE levels, which can be a strong trigger of infiltration
by T cells, eosinophils, mast cells, macrophages, and
keratinocytes [2].
Macrophages have a central role in the production of
proinflammatory mediators during the inflammation
response. Of the various proinflammatory mediators,
nitrite and PGE2 have been found to be important in
several physiological processes, including vasodilation,
neurotransmission, blood coagulation, and immune regu-
lation [19]. NO is synthesized by inducible NO synthase
(iNOS), while PGE2 is produced by cyclooxygenase 2
(COX-2) [20,21]. They aggravate the inflammatory re-
sponses of atopic lesions, which are important feature is of
atopic dermatitis [22]. In our study, we found that MAEFigure 6 Effects of MAE on the plasma levels of IgE and histamine in
IgE and histamine levels were measured in plasma samples from normal co
group (Biostir-AD plus vehicle-treated mice), Tacrolimus group (Biostir-AD p
(Biostir-AD plus MAE-treated mice; 10 mg/mouse). The plasma concentratio
are expressed the as mean ± SEM (n = 5). #, ## P < 0.05 and P < 0.01 vs contrreduced NO and PGE2 production in a dose-dependent
manner in LPS stimulated RAW 264.7 macrophage cells.
Keratinocytes produce chemokines and these factors
are involved with the development of inflammatory skin
diseases, such as atopic dermatitis [23]. Chemokines can
lead to a Th1/Th2 imbalance, which results in the devel-
opment of atopic dermatitis lesions [4]. The lymphocytes
that are directed to the skin have recently been shown to
express CC chemokine receptor 4, which is the receptor
for the CC chemokine TARC. TARC is overexpressed
by keratinocytes, especially in the epidermis of atopic
dermatitis lesions in the murine model and atopic
dermatitis patients [2]. In this study, MAE inhibited TARC
production in TI-stimulated HaCaT cells. Overall, these re-
sults suggest that MAE is effective in suppressing inflam-
matory responses and the development of atopic dermatitis
by reducing TARC production.house dust mite-induced atopic dermatitis in NC/Nga mice. The
ntrol group (vehicle-treated mice; 70% ethanol, 200 μL/mouse), Biostir
lus Tacrolimus ointment-treated mice; 50 mg/mouse), and MAE group
ns of IgE (A) and histamine (B) were measured by ELISA. The values
ol group, respectively; * P < 0.05 vs Biostir-AD-treated mice.
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atopic dermatitis and share the clinical features of hu-
man atopic dermatitis [24]. NC/Nga mice with atopic
dermatitis exhibit various histopathological and patho-
physiological changes compared with normal mice [25].
The elevation of proinflammatory cytokines, IgE, and
histamine are important features in the pathophysiology
of NC/Nga mice with atopic dermatitis [4]. Inflammatory
cell infiltration, epidermis hypertrophy, intracellular edema,
and hyperkeratosis are mainly observed in atopic dermatitis
skin lesions [26]. Our study also observed the characteristic
pathophysiological alterations of atopic dermatitis. NC/Nga
mice where atopic dermatitis was induced by house dust
mites exhibited increased levels of IgE and histamine in
their plasma compared with normal mice. They also ex-
hibited epidermis hypertrophy, intracellular edema, and
infiltration of inflammatory cells in their skin lesions. By
contrast, MAE-treated NC/Nga mice had reduced histo-
pathological changes in their skin lesions and lower
plasma IgE and histamine levels. Based on these findings, a
topical application of MAE may be effective for suppressing
the atopic dermatitis induced by house dust mites.
Topical steroids, emollients, and oral anti-histamines
are used as the first-line therapy for atopic dermatitis
[27]. Steroids are generally prescribed to control the
symptoms of atopic dermatitis, but their repeated use
can cause severe skin atrophy, susceptibility to infec-
tions, and other side effects. These profound side effects
mean that chronic usage must be actively avoided. Thus,
there is a strong need for the development of a herbal
medicine that is effective for the treatment of atopic
dermatitis, which should be safe and eco-friendly.
Conclusions
Our study demonstrated the inhibitory effects of MAE
on atopic dermatitis. The inhibition of NO and PGE2
production was responsible for the anti-inflammatory
effects of MAE, which may be associated with its in-
hibitory effect on TARC production by keratinocytes
in dermatitis lesions. MAE also appeared to reduce the
skin symptoms of atopic dermatitis, such as erythema,
hemorrhage, and edema. The topical application of MAE
significantly reduced the development of house dust
mite-induced atopic dermatitis in NC/Nga mice. Over-
all, these findings provide scientific evidence that MAE
has the potential to be developed as a therapeutic agent
for the treatment of atopic dermatitis.
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